National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014

Reagan‐Steiner, Sarah; Yankey, David; Jeyarajah, Jenny; Elam–Evans, Laurie D.; Singleton, James A.; Curtis, C. Robinette; MacNeil, Jessica R.; Markowitz, Lauri E.; Stokley, Shannon

doi:10.15585/mmwr.mm6429a3

Cited by 392 publications

(367 citation statements)

References 2 publications

(1 reference statement)

Supporting

Mentioning

352

Contrasting

Unclassified

Order By: Relevance

“…1,2 Despite national guidelines for the routine administration of HPV vaccine to 11-and 12-year-old adolescents, only 40% of girls and 22% of boys completed the 3-dose series in 2014. 3 These persistently low levels of coverage have prompted a rapid growth in the research literature on determinants of HPV vaccination, and this work has consistently highlighted the powerful influence of healthcare providers' communication. Adolescents who receive a provider's recommendation have substantially higher odds of initiating HPV vaccination compared to those who do not.…”

Section: Introductionmentioning

confidence: 99%

Provider communication about HPV vaccination: A systematic review

Gilkey

McRee

2016

Human Vaccines & Immunotherapeutics

245

220

View full text Add to dashboard Cite

Background. Improving HPV vaccination coverage in the US will require healthcare providers to recommend the vaccine more effectively. To inform quality improvement efforts, we systematically reviewed studies of provider communication about HPV vaccination. Methods. We searched MEDLINE, CINAHL, EMBASE, and POPLINE in August 2015 to identify studies of provider communication about HPV vaccination. Results. We identified 101 qualitative and quantitative studies. Providers less often recommended HPV vaccine if they were uncomfortable discussing sex, perceived parents as hesitant, or believed patients to be low risk. Patients less often received recommendations if they were younger, male, or from racial/ethnic minorities. Despite parents' preference for unambiguous recommendations, providers often sent mixed messages by failing to endorse HPV vaccine strongly, differentiating it from other vaccines, and presenting it as an "optional" vaccine that could be delayed. Conclusion. Interventions are needed to help providers deliver effective recommendations in the complex communication environment surrounding HPV vaccination.

show abstract

Section: Introductionmentioning

confidence: 99%

Provider communication about HPV vaccination: A systematic review

Gilkey

McRee

2016

Human Vaccines & Immunotherapeutics

245

220

View full text Add to dashboard Cite

show abstract

“…By 2012, two-dose varicella vaccination coverage levels approached the two-dose coverage levels of 82-94% seen for measles, mumps, and rubella (MMR), and wider adoption of two-dose varicella vaccination requirements for school entry have been instrumental in progression toward the Healthy People 2020 (HP2020) target of 95% of kindergarten children receiving two doses of varicella vaccine [5]. Despite this progress, estimated 2015 two-dose varicella vaccination coverage of 84.6% for adolescents aged 13-15 falls below the HP2020 target of 90% [6].…”

Section: Introductionmentioning

confidence: 99%

Varicella seroepidemiology in United States air force recruits: A retrospective cohort study comparing immunogenicity of varicella vaccination and natural infection

Duncan

Witkop

Webber

et al. 2017

Vaccine

View full text Add to dashboard Cite

seroepidemiology in United States air force recruits: A retrospective cohort study comparing immunogenicity of varicella vaccination and natural infection" (2017 a b s t r a c tBackground/Objectives: Infection with varicella zoster virus (VZV) produces lifelong immunity, but duration of post-vaccination immunity has not been established. The purpose of this study is to determine if a difference exists in the long-term seropositivity of anti-VZV antibodies in a cohort of young adults who were vaccinated against varicella as compared to a similar cohort with a history of chickenpox disease, and to determine which variables best predict waning seropositivity following varicella vaccination. Methods: This retrospective cohort study captures immunization and serology data from approximately 10,000 recruits who entered basic military training between January 1, 2008, and December 31, 2015, and who have childhood immunization records in the Air Force Aeromedical Services Information Management System. Varicella vaccine immunogenicity was determined relative to the immunogenicity of chickenpox disease, as measured by multiplex flow immunoassay. Among vaccine recipients, waning seroimmunity was modeled and adjusted for several important covariates. Results: Basic military trainees who received varicella vaccine in childhood were 24% less likely to be seropositive to VZV than trainees who were exempt from vaccine due to a history of chickenpox disease. There was no significant difference in seropositivity between male and female trainees. The odds of a vaccinated trainee being seropositive to VZV decreased by 8% with each year elapsed since vaccination. Seroprevalence declined below estimated herd immunity thresholds in vaccinated trainees born after 1994, and in the cohort as a whole for trainees born after 1995. Conclusion: Despite prior vaccination, seroimmunity in a large cohort of young adults unexposed to wildtype VZV failed to meet the estimated threshold for herd immunity. If vaccination in accordance with the current US VZV vaccination schedule is inadequate to maintain herd immunity, young adults not previously exposed to wild-type VZV may be at increased risk for varicella outbreaks.Published by Elsevier Ltd.

show abstract

“…18 Additionally, adolescents have a more robust immune response to the vaccine than when received as an adult. 18 However, because the majority of adolescents are incompletely vaccinated, 19 it becomes important to promote uptake and completion of the HPV vaccine during the catch-up period.…”

Section: Discussionmentioning

confidence: 99%

“…2 In the United States, the rates of HPV vaccine initiation and completion are low. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination of adolescents age 11-12 with a catch up period for females during the ages of [13][14][15][16][17][18][19][20][21][22][23][24][25][26]. 3 Despite recommendations, in a 2013 nationwide survey of 2077 women aged 19-26 years of age, only 37% reported previously receiving at least one HPV vaccine.…”

mentioning

confidence: 99%

Low Uptake of Human Papillomavirus Vaccine Among Postpartum Women, 2006–2012

Kilfoyle

Rahangdale

Dusetzina

2016

Journal of Women's Health

View full text Add to dashboard Cite

Background: Young adult women find it acceptable to be offered the human papillomavirus (HPV) vaccine postpartum. Little is known about the practice of administering the HPV vaccine during the postpartum period. Materials and Methods: The Truven Health Analytics MarketScan Commercial Claims and Encounters database was used to develop a cohort of privately insured 18 to 26-year-old women with uncomplicated live-born pregnancies. Eligibility required no previous doses of HPV vaccine before delivery and continuous insurance enrollment from June 2006 through 1 year postpartum. Descriptive statistics were performed. Results: A total of 51,913 women meet age and enrollment criteria, with 3912 (7.5%) having received any doses of vaccine before their delivery, leaving 48,001 women in this cohort. In the year postpartum, 861 women (1.8%) received any HPV vaccine. Of the women initiating the vaccine, only 337 (39%) completed the threevaccine series. Women who received the vaccine, compared with women who did not, were younger (21 vs. 23 years old), more often the dependent to the insurance beneficiary (56% vs. 30%), and were more likely to have had an abnormal pap smear in the year prior (19.6% vs. 9.1%) or postdelivery (16.4% vs. 4.9). More women completed the HPV vaccine series when initiated within 2 months postpartum compared with women initiating the vaccine series >2 months postpartum (44% vs. 38%). Conclusions: Postpartum women are eligible for the HPV vaccine, yet very few are receiving it. The postpartum period is a missed opportunity for administration of this cancer-preventing vaccine.

show abstract

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014

Cited by 392 publications

References 2 publications

Provider communication about HPV vaccination: A systematic review

Provider communication about HPV vaccination: A systematic review

Varicella seroepidemiology in United States air force recruits: A retrospective cohort study comparing immunogenicity of varicella vaccination and natural infection

Low Uptake of Human Papillomavirus Vaccine Among Postpartum Women, 2006–2012

Contact Info

Product

Resources

About